| Factor Information | |
|---|---|
| Data ID | 409 |
| Factor | Soluble suppression of tumorogenicity 2 (sST2) |
| Description | Soluble suppression of tumorogenicity 2 (sST2) has been shown to be of prognostic value in patients with chronic and acute left heart failure. |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | to assess the predictive value of sST2 levels in adult patients with complex congenital heart disease (CHD). |
| p Value | 0.007 |
| Conclusion | In patients with complex CHD, sST2 were significant higher in SRV, FONT and EIS patients than that in controlsl. It may have additive value to natriuretic peptides for the prediction of all-cause mortality |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 448 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | CRHD/other/SRV/EIS/complex CHD |
| Reference | |
|---|---|
| PMID | 30118521 |
| Year | 2018 |
| Title | Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | Blood | |
| Region | Homburg/Saar,Germany | |
| Method | In all participants, venous blood samples were drawn into standard sampling tubes after echocardiography. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | CHD patients(Treatment) | healthy controls(Control) |
| Number | 169 | 32 |
| Age | 28.2 ± 12.0 years (range 11±73 years) | 29.6 ± 15.2 years (range 11±61 years) |
| Gender (Male: Female) | 85:84 | N/A |
| Marker Level | 29.7 (24.5±37.6) ng/ml | 26.4 (23.0±30.5) ng/ml |
